


Short-lived antibody-mediated saliva immunity against SARS-CoV-2 after vaccination**Supplemental information:****Table of contents:**

Supplementary Figures: 2

Supplementary Figure 1. Validation tests of antibodies in saliva against RBD from SARS-CoV-2 in the Luminex assay 2

Supplementary Figures:

Supplementary Figure 1. Validation tests of antibodies in saliva against RBD from SARS-CoV-2 in the Luminex assay. Boxplots showing the level of antibodies in Log₁₀(Fluorescence Intensity [FI]) in convalescent individuals and infection-naïve individuals. SARS-CoV-2 infection was confirmed by a positive RT-PCR result. All samples were collected before vaccination. Levels of IgG antibodies (A), levels of IgA antibodies (B), and levels of IgM antibodies (C) in convalescent and infection-naïve individuals. The horizontal dotted line indicates the assay cutoff. The p-values have been calculated using a Mann-Whitney test. $p < 0.05$ was considered significant.